Cargando…
Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methyl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043709/ https://www.ncbi.nlm.nih.gov/pubmed/24920885 http://dx.doi.org/10.2147/DDDT.S56625 |
_version_ | 1782318970632667136 |
---|---|
author | Winter, Evelyn Gozzi, Gustavo Jabor Chiaradia-Delatorre, Louise Domeneghini Daflon-Yunes, Nathalia Terreux, Raphael Gauthier, Charlotte Mascarello, Alessandra Leal, Paulo César Cadena, Silvia M Yunes, Rosendo Augusto Nunes, Ricardo José Creczynski-Pasa, Tania Beatriz Di Pietro, Attilio |
author_facet | Winter, Evelyn Gozzi, Gustavo Jabor Chiaradia-Delatorre, Louise Domeneghini Daflon-Yunes, Nathalia Terreux, Raphael Gauthier, Charlotte Mascarello, Alessandra Leal, Paulo César Cadena, Silvia M Yunes, Rosendo Augusto Nunes, Ricardo José Creczynski-Pasa, Tania Beatriz Di Pietro, Attilio |
author_sort | Winter, Evelyn |
collection | PubMed |
description | A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methylenedioxyphenyl while an intermediate inhibitory activity was obtained with a 1-naphthyl group. In all cases, two or three methoxy groups had to be present on the phenyl A-ring to produce a maximal inhibition. Molecular modeling indicated both electrostatic and steric positive contributions. A higher potency was observed when the 2-naphthyl or 3,4-methylenedioxyphenyl group was shifted to the A-ring and methoxy substituents were shifted to the phenyl B-ring, indicating preferences among polyspecificity of inhibition. |
format | Online Article Text |
id | pubmed-4043709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40437092014-06-11 Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position Winter, Evelyn Gozzi, Gustavo Jabor Chiaradia-Delatorre, Louise Domeneghini Daflon-Yunes, Nathalia Terreux, Raphael Gauthier, Charlotte Mascarello, Alessandra Leal, Paulo César Cadena, Silvia M Yunes, Rosendo Augusto Nunes, Ricardo José Creczynski-Pasa, Tania Beatriz Di Pietro, Attilio Drug Des Devel Ther Original Research A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methylenedioxyphenyl while an intermediate inhibitory activity was obtained with a 1-naphthyl group. In all cases, two or three methoxy groups had to be present on the phenyl A-ring to produce a maximal inhibition. Molecular modeling indicated both electrostatic and steric positive contributions. A higher potency was observed when the 2-naphthyl or 3,4-methylenedioxyphenyl group was shifted to the A-ring and methoxy substituents were shifted to the phenyl B-ring, indicating preferences among polyspecificity of inhibition. Dove Medical Press 2014-05-27 /pmc/articles/PMC4043709/ /pubmed/24920885 http://dx.doi.org/10.2147/DDDT.S56625 Text en © 2014 Winter et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Winter, Evelyn Gozzi, Gustavo Jabor Chiaradia-Delatorre, Louise Domeneghini Daflon-Yunes, Nathalia Terreux, Raphael Gauthier, Charlotte Mascarello, Alessandra Leal, Paulo César Cadena, Silvia M Yunes, Rosendo Augusto Nunes, Ricardo José Creczynski-Pasa, Tania Beatriz Di Pietro, Attilio Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title | Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title_full | Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title_fullStr | Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title_full_unstemmed | Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title_short | Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position |
title_sort | quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein abcg2: polyspecificity at b-ring position |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043709/ https://www.ncbi.nlm.nih.gov/pubmed/24920885 http://dx.doi.org/10.2147/DDDT.S56625 |
work_keys_str_mv | AT winterevelyn quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT gozzigustavojabor quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT chiaradiadelatorrelouisedomeneghini quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT daflonyunesnathalia quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT terreuxraphael quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT gauthiercharlotte quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT mascarelloalessandra quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT lealpaulocesar quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT cadenasilviam quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT yunesrosendoaugusto quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT nunesricardojose quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT creczynskipasataniabeatriz quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition AT dipietroattilio quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition |